E-LIB Suche - Ergebnisse für: Damaraju, C.

1

PCV8 Impct of Comorbidities on Time in Therapeutic Range in..:

Choi, J.C. ; Damaraju, C. ; Mills, R.M....
Value in Health. 15 (2012) 4 - p. A112-A113 , 2012

Link: https://doi.org/10.1016/..

2

PMH85 PATTERNS OF AUGMENTATION OF EXTENDED-RELEASE STIMULAN..:

Xiao, X ; Damaraju, C ; Durkin, M
Value in Health. 12 (2009) 3 - p. A188-A189 , 2009

Link: https://doi.org/10.1016/..

3

PMH82 PATTERNS OF AUGMENTATION OF EXTENDED-RELEASE STIMULAN..:

Xiao, X ; Damaraju, C ; Durkin, M
Value in Health. 12 (2009) 3 - p. A188 , 2009

Link: https://doi.org/10.1016/..

4

PMH56 MEDICATION SATISFACTION IN SUBJECTS WITH SCHIZOPHRENI..:

Canuso, CM ; Grinspan, A ; Merriman, UE...
Value in Health. 12 (2009) 3 - p. A183 , 2009

Link: https://doi.org/10.1016/..

5

Does early detection of atrial fibrillation reduce the risk..:

Gibson, C. Michael ; Steinhubl, Steven ; Lakkireddy, Dhanunjaya...
American Heart Journal. 259 (2023) - p. 30-41 , 2023

Link: https://doi.org/10.1016/..

6

The SGLT2 inhibitor canagliflozin in heart failure: the CHI..:

Spertus, John A. ; Birmingham, Mary C. ; Nassif, Michael...
Nature Medicine. 28 (2022) 4 - p. 809-813 , 2022

Link: https://doi.org/10.1038/..

7

Canagliflozin Reduces All-cause Hospitalization in Patients..:

Feng, Kent Y. ; Gogate, Jagadish ; Damaraju, C.V....
Metabolism. 116 (2021) - p. 154509 , 2021

Link: https://doi.org/10.1016/..

8

Rivaroxaban thromboprophylaxis for gastric/gastroesophageal..:

Mones, Jodi V. ; Streiff, Michael B. ; Khorana, Alok A....
Research and Practice in Thrombosis and Haemostasis. 5 (2021) 5 - p. e12549 , 2021

Link: https://doi.org/10.1002/..

9

Effects of canagliflozin on major adverse cardiovascular ev..:

Weir, Matthew R. ; Gogate, Jagadish ; Damaraju, C.V...
Diabetes, Obesity and Metabolism. 24 (2021) 1 - p. 12-20 , 2021

Link: https://doi.org/10.1111/..

10

OC-12 D-dimer levels significantly decline in ambulatory ca..:

Vadhan-Raj, S. ; Kuderer, N.M. ; Wun, T....
Thrombosis Research. 200 (2021) - p. S12 , 2021

Link: https://doi.org/10.1016/..

11

Effects of canagliflozin on cardiovascular death and hospit..:

Mahaffey, K.W ; Bakris, G ; Blais, J...
European Heart Journal. 41 (2020) Supplement_2 - p. , 2020

Link: https://doi.org/10.1093/..

12

Rivaroxaban for Preventing Venous Thromboembolism in High-R..:

Khorana, Alok ; Vadhan-Raj, Saroj ; Kuderer, Nicole...
Thrombosis and Haemostasis. 117 (2017) 11 - p. 2135-2145 , 2017

Link: https://doi.org/10.1160/..

13

Response to Stavropoulos:

Townsend, Raymond R. ; Machin, Israel ; Ren, Jimmy...
The Journal of Clinical Hypertension. 18 (2016) 10 - p. 1074-1075 , 2016

Link: https://doi.org/10.1111/..

14

Effect of canagliflozin on serum uric acid in patients with..:

Davies, M. J. ; Trujillo, A. ; Vijapurkar, U...
Diabetes, Obesity and Metabolism. 17 (2015) 4 - p. 426-429 , 2015

Link: https://doi.org/10.1111/..

15

Benefit-Risk Evaluation and Decision Making: Some Practical..:

Colopy, Michael W. ; Damaraju, C. V. ; He, Weili...
Therapeutic Innovation & Regulatory Science. 49 (2015) 3 - p. 425-433 , 2015

Link: https://doi.org/10.1177/..